Loading…
CARVEDILOL is a brand name for Carvedilol. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Symptomatic chronic heart failure (CHF) Carvedilol is indicated for the treatment of stable mild, moderate and severe chronic heart failure as adjunct to standard therapies e.g. diuretics, digoxin and ACE inhibitors in patients with euvolemia. Hypertension Carvedilol is indicated for the treatment of hypertension.…
Verbatim from this product's MHRA label. Tap a section to expand.
For oral administration. The tablets should be taken with fluid. For CHF patients carvedilol should be given with food. Symptomatic chronic heart failure Initiation of therapy with carvedilol should only be under the supervision of a hospital physician, following a thorough assessment of the patients' condition.
Prior to any subsequent titration of the dose, the patient must be clinically evaluated on the day of up - titration by a health-care professional experienced in the management of heart failure to ensure that the clinical status has remained stable.
The dose of carvedilol should not be increased in any patient with deteriorating heart failure since last visit or with signs of decompensated or unstable chronic heart failure. The dosage must be titrated to individual requirements.
For those patients receiving diuretics and/or digoxin and/or ACE inhibitors, dosing of these other drugs should be stabilized prior to initiation of carvedilol treatment. 125 mg twice a day for two weeks. 5 mg twice daily and thereafter 25 mg twice daily.
Dosing should be increased to the highest level tolerated by the patient. ). In patients with mild or moderate CHF weighing more than 85kg, the recommended maximum dose is 50 mg twice daily. During up-titration of the dose in patients with systolic blood pressure < 100mmHg, deterioration of renal and/or cardiac functions may occur.
Therefore, before each dose increase these patients should be evaluated by the physician for renal function and symptoms of worsening heart failure or vasodilation. Transient worsening of heart failure, vasodilation or fluid retention may be treated by adjusting doses of diuretics or ACE inhibitors or by modifying or temporarily discontinuing carvedilol treatment.
Under these circumstances, the dose of carvedilol should not be increased until symptoms of worsening heart failure or vasodilation have been stabilised. 125 mg twice daily and up-titrated in line with the above dosing recommendation.
Elderly As for adults. Children Safety and efficacy in children (under 18 years) has not been established. Hypertension Once daily dosing is recommended. 5 mg once a day for the first two days. Thereafter the recommended dosage is 25 mg once a day.
Although this is an adequate dose in most patients, if necessary the dose may be titrated up to a recommended daily maximum dose of 50 mg given once a day or in divided doses. Dose titration should occur at intervals of at least two weeks.
a) Summary of the safety profile The frequency of adverse reactions is not dose dependent, with the exception of dizziness, abnormal vision and bradycardia. b) Tabulated list of adverse reactions The risk of most adverse reactions associated with carvedilol is similar across all indications.
Exceptions are described in subsection (c).
Frequency categories are as follows:
Adverse drug reactions are listed below by system organ class and frequency. 4) Cardiac disorders Atrioventricular-block, angina pectoris Skin and subcutaneous tissue disorder Dermatitis, increased sweating, alopecia Uncommon (>1/1000, <1/100) Nervous system disorders Presyncope, syncope Rare (>1/10000,<1/1000) Blood and lymphatic system disorders Thrombocytopenia Very rare (incl.
g. 5) In patients with hypertension and angina The profile is similar to that observed in chronic heart failure although the incidence of events is generally lower in patients with hypertension or angina treated with carvedilol. Frequency System organ class Adverse events Cardiac disorders Cardiac failureVery common (> 1/10) Vascular disorders Hypotension Infections and infestations Bronchitis, pneumonia, upper respiratory tract infection, urinary tract infection Blood and lymphatic system disorders Anaemia Psychiatric disorder Depression and depressed mood Nervous system disorders Dizziness, fatigue, headache: usually mild, occur particularly at the start of treatment Eye disorders Lacrimation decreased (dry eye), visual impairment, eye irritation Common (>1/100, <1/10) Cardiac disorders Bradycardia, postural hypotension, Frequency System organ class Adverse events especially at the beginning of treatment.
Vascular disorders Orthostatic hypotension, disturbances of peripheral circulation (cold extremities, peripheral vascular disease, exacerbation of intermittent claudication and Raynaud’s phenomenon) Respiratory, thoracic and mediastinal disorders Dyspnea, pulmonary oedema and asthma in predisposed patients Gastro-intestinal disorders Gastro-intestinal upset (with symptoms such as abdominal pain, dyspepsia, diarrhoea, nausea) Musculoskeletal and connective tissue disorder Pain in the extremities Renal and urinary disorders Micturition disorder General disorder Pain Nervous system disorders Asthenia, syncope, paraesthesia Psychiatric disorder Sleep disorder Eye disorders Disturbed vision Cardiovascular system Angina pectoris (including chest pain), AV- block, symptoms of heart failure and peripheral oedema.
2 Pharmacokinetic properties). For oral administration. The tablets should be taken with fluid. For CHF patients carvedilol should be given with food. Initiation of therapy with carvedilol should only be under the supervision of a hospital physician, following a thorough assessment of the patients' condition.
Prior to any subsequent titration of the dose, the patient must be clinically evaluated on the day of up - titration by a health-care professional experienced in the management of heart failure to ensure that the clinical status has remained stable.
The dose of carvedilol should not be increased in any patient with deteriorating heart failure since last visit or with signs of decompensated or unstable chronic heart failure. The dosage must be titrated to individual requirements.
For those patients receiving diuretics and/or digoxin and/or ACE inhibitors, dosing of these other drugs should be stabilized prior to initiation of carvedilol treatment. 125 mg twice a day for two weeks. 5 mg twice daily and thereafter 25 mg twice daily.
Dosing should be increased to the highest level tolerated by the patient. ). In patients with mild or moderate CHF weighing more than 85kg, the recommended maximum dose is 50 mg twice daily. During up-titration of the dose in patients with systolic blood pressure < 100mmHg, deterioration of renal and/or cardiac functions may occur.
Therefore, before each dose increase these patients should be evaluated by the physician for renal function and symptoms of worsening heart failure or vasodilation. Transient worsening of heart failure, vasodilation or fluid retention may be treated by adjusting doses of diuretics or ACE inhibitors or by modifying or temporarily discontinuing carvedilol treatment.
Under these circumstances, the dose of carvedilol should not be increased until symptoms of worsening heart failure or vasodilation have been stabilised. 125 mg twice daily and up-titrated in line with the above dosing recommendation.
2 Pharmacokinetic properties). Patients with co-existing renal dysfunction No dose adjustment is anticipated as long as systolic blood pressure is above 100mm Hg (see also sections
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
5 mg daily is recommended. This has provided satisfactory control in some cases. If the response is inadequate the dose may be titrated up to the recommended daily maximum dose of 50 mg given once a day or in divided doses. Children Safety and efficacy in children (under 18 years) has not been established.
5 mg twice a day for the first two days. Thereafter, the recommended dosage is 25 mg twice a day. Elderly The recommended maximum daily dose is 50 mg given in divided doses. Children Safety and efficacy in children (under 18 years) has not been established.
Patients with co-existing hepatic disease Carvedilol is contra-indicated in patients with hepatic dysfunction (see sections
Gastro-intestinal Disorders Constipation, vomiting Skin and subcutaneous tissue disorder Skin reactions (eg allergic exanthema, dermatitis, increased sweating, lichen planus-like skin lesions, pruritus, urticaria). Psoriatic skin lesions may occur or existing lesions exacerbated.
Alopecia Uncommon (>1/1000, <1/100) Reproductive system Sexual impotence, erectile dysfunction Rare (>1/10000, <1/1000) Respiratory, thoracic and mediastinal disorders Flu-like symptoms, nasal congestion, wheezing Gastro-intestinal disorders Dryness of the mouth Very rare (incl.
g. Erythema mulitforme, Stevens-Johnson syndrome, Toxic epidermal necrolysis) (c) Description of selected adverse reactions Dizziness, syncope, headache and asthenia are usually mild and are more likely to occur at the beginning of treatment.
4). Cardiac failure is a commonly reported adverse event in both placebo and carvedilol- […]
Elderly As for adults. Children Safety and efficacy in children (under 18 years) has not been established. Hypertension Once daily dosing is recommended. 5 mg once a day for the first two days. Thereafter the recommended dosage is 25 mg once a day.
Although this is an adequate dose in most patients, if necessary the dose may be titrated up to a recommended daily maximum dose of 50 mg given once a day or in divided doses. Dose titration should occur at intervals of at least two weeks.
5 mg daily is recommended. This has provided satisfactory control in some cases. If the response is inadequate the dose may be titrated up to the recommended daily maximum dose of 50 mg given once a day or in divided doses. Children Safety and efficacy in children (under 18 years) has not been established.
5 mg twice a day for the first two days. Thereafter, the recommended dosage is 25 mg twice a day. Elderly The recommended maximum daily dose is 50 mg given in divided doses. Children Safety and efficacy in children (under 18 years) has not been established.
2 Pharmacokinetic properties). 2 Pharmacokinetic properties). 1. • Carvedilol is contra-indicated in patients with marked fluid retention or overload requiring intravenous inotropic support. • Patients with obstructive airways disease, unstable/decompensated heart failure, clinically manifested liver dysfunction.
• As with other beta-blocking agents: History of bronchospasm or asthma, 2nd and 3rd degree A-V heart block (unless a permanent pacemaker is in place), severe bradycardia (< 50 bpm), cardiogenic shock, sick sinus syndrome (including sino- atrial block), severe hypotension (systolic blood pressure < 85 mmHg), metabolic acidosis and phaeochromocytoma (unless adequately controlled by alpha blockade).
• Prinzmetal's angina. • Severe peripheral arterial circulatory disturbances. 5). • Unsuitable for patients with lactase insufficiency, galactosaemia or glucose/galactose malabsorption syndrome. 4 Special warnings and precautions for use Chronic Heart Failure In chronic heart failure patients, worsening cardiac failure or fluid retention may occur during up-titration of carvedilol.
If such symptoms occur, the dose of diuretic should be increased and the carvedilol dose should not be advanced until clinical stability resumes. Occasionally it may be necessary to lower the carvedilol dose or in rare cases, temporarily discontinue it.
Such episodes do not preclude subsequent successful titration of carvedilol. 5). In hypertensive patients who have chronic heart failure controlled with digoxin, diuretics and/or an ACE inhibitor, carvedilol should be used with caution since both digoxin and carvedilol may slow A-V […]